Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

New Upgrade:   Dedicated Screeners for Stocks & ETFs

Learn more
Market News Market Pulse Stocks News ETF News Crypto News

Structure Therapeutics Inc.

Contributing Author

Recent Articles by Structure Therapeutics Inc.

Oct-19
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2026 GPCR GlobeNewswire
Sep-08
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management GPCR -14.70% GlobeNewswire
Sep-03
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
Aug-06
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights GPCR GlobeNewswire
Jun-05
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity GPCR GlobeNewswire
May-26
Structure Therapeutics Announces Participation in Upcoming Investor Conferences GPCR GlobeNewswire
May-07
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights GPCR GlobeNewswire
Apr-27
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions GPCR GlobeNewswire
Apr-14
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel GPCR GlobeNewswire
Mar-16
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +5.40% GlobeNewswire
Feb-26
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Dec-17
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity GPCR GlobeNewswire
Dec-11
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs GPCR GlobeNewswire
Dec-09
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants GPCR GlobeNewswire
Dec-08
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GPCR +102.49% GlobeNewswire
Dec-08
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +102.49% GlobeNewswire
Dec-07
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GPCR GlobeNewswire
Nov-06
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Sep-02
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
Aug-06
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Jun-20
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 GPCR GlobeNewswire
May-29
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
May-08
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)